Actively Recruiting
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Led by International AIDS Vaccine Initiative · Updated on 2026-04-15
112
Participants Needed
2
Research Sites
118 weeks
Total Duration
On this page
Sponsors
I
International AIDS Vaccine Initiative
Lead Sponsor
B
Biomedical Advanced Research and Development Authority
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
CONDITIONS
Official Title
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults in good general health
- Age between 18 and 50 years
- Willing to follow study requirements and attend all follow-up visits
- Agree to HIV testing, risk counseling, and receiving HIV test results
- Sexually active participants must consistently use condoms for 3 months after vaccination
- Individuals able to become pregnant must use effective contraception from 2 weeks before until 3 months after vaccination
- Willing to have urine pregnancy tests as scheduled
- Agree not to donate blood or tissues from screening through the study duration
You will not qualify if you...
- History of immunodeficiency, autoimmune disease, splenectomy, or cancer in the past 5 years
- Use of corticosteroids, immunosuppressive, anticancer, or significant medications within 6 months
- Body mass index (BMI) of 35.0 kg/m2 or higher
- Any progressive or serious acute or chronic medical condition
- Pregnant or breastfeeding individuals
- Diagnosed bleeding disorder
- Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B, current hepatitis C, active syphilis, or long COVID-19 syndrome
- Serious infections requiring intravenous antibiotics, antivirals, or antifungals within 30 days before enrollment
- Abnormal lab tests at screening
- Received live vaccines within 14 to 30 days before or planned soon after vaccination
- Blood transfusion within 3 months prior to enrollment
- Previous exposure to Marburg Virus or history of hemorrhagic fever
- Prior receipt of VSV-vectored, Marburg, or filovirus vaccines or monoclonal/polyclonal antibodies against filoviruses within 12 months
- Participation in another clinical trial within 3 months prior to enrollment
- History of severe vaccine reactions or severe allergies to vaccine components
- Neuropsychiatric conditions or substance abuse affecting safety or protocol compliance
- Living or working with individuals at higher risk from live viral vaccines like infants, elderly, or immunocompromised persons
- Investigator's judgment that participation is not in the participant's best interest
- History of long-term arthritis treatment of 4 weeks or more
- Current rash or history of severe, chronic, or frequent rash
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
George Washington University
Washington D.C., District of Columbia, United States, 20052
Actively Recruiting
2
Johnson County Clin-Trials
Lenexa, Kansas, United States, 66219
Actively Recruiting
Research Team
J
Johannes Beeslaar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here